In mice, a redesigned protein helped an anemia drug take 5.2 times as long to fall to half its blood level. Researchers linked Albumin, a blood protein, to erythropoietin, or EPO. EPO is a drug that helps the body make RBC (Red Blood Cells). It treats anemia, a shortage of these cells. Current EPO drugs may need injections several times a week. The team tested a redesigned form of Albumin against its usual form. They used mice with a human version of a protein that helps Albumin stay in the blood. This was a mouse study, not a test in people. After injection into a vein, the redesigned drug took 5.2 times longer to drop by half. The comparison was EPO joined to ordinary Albumin, not EPO alone. An injection under the skin gave a similar lasting effect. The researchers also compared it with darbepoetin alfa, an existing anemia drug. The redesigned drug produced a longer-lasting rise in red cell counts. When given through the nose, it reached five times the blood levels of darbepoetin alfa. That route also produced a longer-lasting rise in red cell counts. The findings suggest a possible path toward less frequent doses or needle-free delivery. They do not show that raising your own Albumin level would help treat anemia. For BioSocial members, drug design and bloodwork targets are different things. When comparing your Albumin results with community peers, this study offers context—not a new target number to chase. What patterns have you noticed in your Albumin results across blood tests?